Lobeglitazone Completed Phase 4 Trials for Non-Alcoholic Fatty Liver Disease (NAFLD) / Type 2 Diabetes Mellitus Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT02285205A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD